Zealand Pharma stock came into today on a strong run, up 22% over the past month and 10% over three months, with investors leaning into its low 3.7x P/E and fresh profitability over the last year. The earnings release keeps that tension front and center. H1 revenue landed at DKK 4.5b, powered by a DKK 3.7b Phase III milestone and a DKK 798m payment from Roche, and management highlighted DKK 14.5b of cash on hand. The question now is how long that earnings and cash firepower can support the story, as current forecasts suggest declines ahead.
Love Zealand Pharma’s low P/E and cash position but uneasy about forecasts that point to weaker earnings ahead? Compare it with other companies that pair solid balance sheets with stronger fundamentals using our list of solid balance sheet and fundamentals stocks (429 results)
Advertisement
Q2 2026 Earnings Summary
- Revenue (Q1 2026 vs. Q1 2025): DKK 34 million vs. DKK 8 million (increase of 325%)
- Net Income or Loss (Q1 2026 vs. Q1 2025): loss of DKK 394 million vs. loss of DKK 335 million (loss widened by 17.6%)
- Basic EPS (Q1 2026 vs. Q1 2025): loss of DKK 5.58 per share vs. loss of DKK 4.74 per share (loss per share widened by 17.7%)
- Pipeline Breadth (Q3 2025 vs. Q2 2025): 3 products in Phase I, 1 in Phase II, 3 in Phase III and 1 in Pre Registration vs. 2 in Phase I, 2 in Phase II, 4 in Phase III and none in Pre Registration (shift in late stage and earlier stage mix)
Prefer clear visuals over another dense block of earnings tables and footnotes? View Zealand Pharma’s full financial picture, including its valuation profile, in our company report for Zealand Pharma
Zealand Pharma’s Obesity Story Clears Key Proof Points
The bullish idea around Zealand Pharma is that it can turn a focused obesity and metabolic pipeline into a durable, multi asset franchise rather than a single drug bet. The H1 update gives hard evidence that this is starting to happen. Petrelintide now has Phase 2 ZUPREME 1 data with sustained double digit weight loss through 42 weeks and placebo like gastrointestinal tolerability, which is exactly the kind of profile needed for a chronic, first line weight management role. Management has committed to a Phase 3 start in H2 2026, so the obesity thesis is now anchored in a registrational plan, not just mid stage data.
On top of that, partner Boehringer Ingelheim’s survodutide program is hitting clinical and metabolic goals in SYNCHRONIZE 1 and SYNCHRONIZE MASLD, triggering milestone revenue and supporting the idea of multiple shots on goal within obesity and related liver disease
Compare Zealand Pharma’s expanding obesity pipeline and recent milestone cash inflows with how institutional analysts are sizing up the stock after the latest DKK341.2 close. Reveal whether the Street thinks this operational progress justifies more upside by checking the consensus price target analysis for Zealand Pharma.
Zealand Pharma Bears Focus On Earnings Quality Gaps
The bearish view on Zealand Pharma is that earnings are fragile because they lean on a few partnered assets, chunky milestones and high R&D requirements. The H1 print gives that criticism some traction. The DKK 4.5b of revenue is heavily concentrated in a DKK 3.7b Phase III milestone and a DKK 798m Roche payment, which are not recurring. At the same time, Q1 2026 still showed a loss of DKK 394m with loss per share widening to DKK 5.58, so operating leverage from the obesity platform is not yet visible.
Bears also worry about execution risk and a thin near term catalyst path. Petrelintide’s Phase 3 start and ZUPREME 2 data are both pushed into H2 2026, and key survodutide readouts are also clustered in 2026. That timing means this report does little to clear near term earnings volatility or concentration concerns
After clustered 2026 trial catalysts and recent earnings volatility, are these issues isolated or early signals of deeper structural problems? Review our full risk analysis for Zealand Pharma which shows 2 important warning signs
Stay Ahead With Simply Wall St
If Zealand Pharma’s mix of milestone driven earnings and obesity pipeline progress has your attention, register for free with Simply Wall St and add it to your Watchlist to track price moves against fair value estimates and wait for an entry point that fits your plan. Once you are invested, keep on top of position size, valuation changes and key news through the Portfolio Command Center so you focus on signals, not noise. For a broader view of what other investors are seeing in Zealand Pharma and similar stocks, tap into the Community to compare theses and sentiment. Spot potential catalysts and red flags early, and focus on staying a step ahead of the market.
Seeking Alternatives Beyond Zealand Pharma?
Fresh ideas do not stay under the radar for long. Spot companies building real momentum before the crowd catches on and before the best entry points are gone
- Spot sturdy compounders that can handle shocks and still keep moving by scanning our curated group of 295 resilient stocks with low risk scores while that resilience is still underpriced.
- Focus on the infrastructure backbone behind AI’s development by tracking carefully filtered 55 AI infrastructure stocks before institutional money fully catches on and changes the opportunity.
- Look at companies linked to the next leg of industrial demand with a hand picked 9 top copper producer stocks set that could react quickly once momentum returns to key supply chains.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it
Discover if Zealand Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition
Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
mitchell_lawler
The Foxhole
People are still arguing about whether Nvidia’s chips are the fastest. What if Jensen just built a moat that has nothing to do with the chips?
1112
PowerLaw14h
I wonder why Jensen is doing this. It just increases the risks of failure multifold
zoe_vi5fn13h
The bearishness in threads like this is itself worth examining. Every large financing innovation has been called a bubble structure at inception, including securitisation of aircraft, of shipping, of fibre and of mortgages, and three of those four turned out to be genuinely useful market infrastructure that lowered the cost of capital for real assets. The failure case gets remembered because it was spectacular
About CPSE:ZEAL
Zealand Pharma
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States
See The Free Research Report
Excellent balance sheet with proven track record
See The Free Research Report
Similar Companies
CPSE:GMAB
Genmab
Eli Lilly
Market Insights
What Korea’s market says about your index fundMitchell Lawler
What does frontier-beating open source mean for AI investors?Andrew Legget
Why 2026’s worst-looking sector might be its most misreadMitchell Lawler
Advertisement
Weekly Picks
RI
Rick_Orfordon Starfighters Space·7 days ago
The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market
Fair Value:US$519.8% undervalued
20followersusers have followed this narrative
·1commentusers have commented on this narrative
·2likesusers have liked this narrative
FU
FundamentalFlowon Vertiv Holdings Co·11 days ago
The Short and Long Term Compounder of Liquid Cooling industry
Fair Value:US$45036.2% undervalued
47followersusers have followed this narrative
·0commentsusers have commented on this narrative
·13likesusers have liked this narrative
JO
John_Ericon SPX Technologies·6 days ago
I Fell in Love With a Data-Center Cooling Stock. Then I Opened the Filings
Fair Value:US$2034.5% overvalued
20followersusers have followed this narrative
·1commentusers have commented on this narrative
·4likesusers have liked this narrative
TR
tripledubon GQG Partners·about 23 hours ago
The Cheap Genius Problem
Fair Value:AU$3.2155.5% undervalued
30followersusers have followed this narrative
·0commentsusers have commented on this narrative
·21likesusers have liked this narrative
RecentlyUpdated Narratives
ZO
zonedinouton Nasdaq·about 6 hours ago
Nasdaq revenue will grow by 7.17% while profit margin surges to 35%
Fair Value:US$104.196.3% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
MR
MRT23on Fiserv·about 9 hours ago
Q1 2026 FCF collapse has reset the debate from “fair value” to “distressed transformation”
Fair Value:US$5011.0% overvalued
5followersusers have followed this narrative
·1commentusers have commented on this narrative
·0likesusers have liked this narrative
MR
MRT23on CorMedix·about 9 hours ago
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
Fair Value:US$1337.4% undervalued
10followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·2 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28019.5% undervalued
306followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 1 month ago
A wonderful business at reasonable price
Fair Value:US$419.9118.3% overvalued
164followersusers have followed this narrative
·0commentsusers have commented on this narrative
·8likesusers have liked this narrative
KI
KiwiInveston Amazon.com·3 months ago
Amazon’s high growth, high tech segments propel its profits, while traditional segments plod along
Fair Value:US$475.0944.2% undervalued
185followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
